132 related articles for article (PubMed ID: 37774895)
21. Berberine prevents NAFLD and HCC by modulating metabolic disorders.
Lin X; Zhang J; Chu Y; Nie Q; Zhang J
Pharmacol Ther; 2024 Feb; 254():108593. PubMed ID: 38301771
[TBL] [Abstract][Full Text] [Related]
22. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles.
Yuan X; Wang J; Tang X; Li Y; Xia P; Gao X
J Transl Med; 2015 Jan; 13():24. PubMed ID: 25623289
[TBL] [Abstract][Full Text] [Related]
23. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
24. Liposomal Silybin Improves Glucose and Lipid Metabolisms in Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease via AMPK/TGF-β1/Smad Signaling.
Cai J; Zhu Y; Li X; Deng G; Han Y; Yuan F; Yi G; Xia X
Tohoku J Exp Med; 2023 Dec; 261(4):257-265. PubMed ID: 37344419
[TBL] [Abstract][Full Text] [Related]
25. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Zhang YP; Deng YJ; Tang KR; Chen RS; Liang S; Liang YJ; Han L; Jin L; Liang ZE; Chen YN; Yang QH
Curr Med Sci; 2019 Feb; 39(1):37-43. PubMed ID: 30868489
[TBL] [Abstract][Full Text] [Related]
26. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model.
Sun R; Xu D; Wei Q; Zhang B; Aa J; Wang G; Xie Y
Biomed Pharmacother; 2020 Mar; 123():109721. PubMed ID: 31865143
[TBL] [Abstract][Full Text] [Related]
27. Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway.
Wei S; Zhang M; Yu Y; Lan X; Yao F; Yan X; Chen L; Hatch GM
PLoS One; 2016; 11(3):e0152097. PubMed ID: 27011261
[TBL] [Abstract][Full Text] [Related]
28. Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease.
Wu J; Lou YG; Yang XL; Wang R; Zhang R; Aa JY; Wang GJ; Xie Y
Acta Pharmacol Sin; 2023 Jan; 44(1):133-144. PubMed ID: 35705686
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease.
Xie J; Li L; Zhao L
Mini Rev Med Chem; 2021; 21(19):3030-3036. PubMed ID: 33820503
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats.
Li QP; Dou YX; Huang ZW; Chen HB; Li YC; Chen JN; Liu YH; Huang XQ; Zeng HF; Yang XB; Su ZR; Xie JH
Phytomedicine; 2021 May; 85():153550. PubMed ID: 33831691
[TBL] [Abstract][Full Text] [Related]
31. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.
Ou Q; Weng Y; Wang S; Zhao Y; Zhang F; Zhou J; Wu X
Dig Dis Sci; 2018 Dec; 63(12):3398-3408. PubMed ID: 30191499
[TBL] [Abstract][Full Text] [Related]
32. Phytosome-nanosuspensions for silybin-phospholipid complex with increased bioavailability and hepatoprotection efficacy.
Chi C; Zhang C; Liu Y; Nie H; Zhou J; Ding Y
Eur J Pharm Sci; 2020 Mar; 144():105212. PubMed ID: 31923602
[TBL] [Abstract][Full Text] [Related]
33. Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.
Lu Z; Lu F; Wu L; He B; Chen Z; Yan M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):383-390. PubMed ID: 32524150
[TBL] [Abstract][Full Text] [Related]
34. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress.
Zhang Z; Li B; Meng X; Yao S; Jin L; Yang J; Wang J; Zhang H; Zhang Z; Cai D; Zhang Y; Ning G
Sci Rep; 2016 Feb; 6():20848. PubMed ID: 26857750
[TBL] [Abstract][Full Text] [Related]
35. Silybin Restored CYP3A Expression through the Sirtuin 2/Nuclear Factor κ-B Pathway in Mouse Nonalcoholic Fatty Liver Disease.
Zhang R; Xu D; Zhang Y; Wang R; Yang N; Lou Y; Zhao H; Aa J; Wang G; Xie Y
Drug Metab Dispos; 2021 Sep; 49(9):770-779. PubMed ID: 34183378
[TBL] [Abstract][Full Text] [Related]
36. Cinnabarinic Acid Provides Hepatoprotection Against Nonalcoholic Fatty Liver Disease.
Patil NY; Rus I; Downing E; Mandala A; Friedman JE; Joshi AD
J Pharmacol Exp Ther; 2022 Oct; 383(1):32-43. PubMed ID: 35933113
[TBL] [Abstract][Full Text] [Related]
37. Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
Zheng C; Nie H; Pan M; Fan W; Pi D; Liang Z; Liu D; Wang F; Yang Q; Zhang Y
J Ethnopharmacol; 2024 Jan; 318(Pt A):116967. PubMed ID: 37506783
[TBL] [Abstract][Full Text] [Related]
38. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
39. Exocarpium Citri Grandis alleviates the aggravation of NAFLD by mitigating lipid accumulation and iron metabolism disorders.
Deng G; Liu C; Zhao J; Wang M; Li Y; Yang M; Ye H; Li J; Qin M; Wu C; Shi H; Liao Y; Zhou Z; Zhang S; Lam Yung KK; Gao L
J Ethnopharmacol; 2023 Sep; 313():116559. PubMed ID: 37116730
[TBL] [Abstract][Full Text] [Related]
40. Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease
Yang S; Cao S; Li C; Zhang J; Liu C; Qiu F; Kang N
Front Pharmacol; 2022; 13():913378. PubMed ID: 35873595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
